Wednesday, June 17, 2020

What's new with the policies in the Chinese Pharma Market?

Explore at the conference webcast with Pharma Intelligence Informa
View this E-mail online
Conference Webcast
Pharmaceutical Market in China:
Policy Reform, Impacts and Opportunities


19 June 2020   16:00-17:00 UTC+8 China Time

Organizer: 
CPhI China 
 
Co-organizer: Pharma Intelligence | Informa

The policy reform is expected to reshape the pharmaceutical market in China.  In this presentation, we shall discuss the followings, but not limited to:
  • The reform streamlines the clinical trials approval process in China, how would it affect the clinical trial landscape? 
  • What kind of drugs would potentially get expedited review and approval in China?
  • What pricing and reimbursement strategies were taken by generics manufactures and innovative drug developers under the downward pricing pressure?
  • What are the incentives for innovation?
  • How to capture and analysis the opportunities for 505(b)(2) drugs, pediatric drugs, orphan drugs, drugs with breakthrough designation?
Keynote Speaker
Dr. Annie Siu (PhD, MBA)
Principal Analyst, Pharma Intelligence | Informa

Dr. Siu is an Associate Professor at the Chinese Academy of Sciences, a Visiting Scientist at the National Cancer Institute of the National Institutes of Health, and an Research Assistant Professor at the State Key Laboratory of the University of Hong Kong. She has been in-charge and participated in several drug research and development projects sponsored by the Ministry of Science and Technology of the People's Republic of China, the National Natural Science Foundation of China, local governments, multinational pharmaceutical companies, and Chinese Biotech companies. 

The conference is only 2 days away!
Register to acquire key knowledge on policies! 
More Learning Opportunities
Date & Time
18 June 2020
14:30-15:15 UTC+8
18 June 2020
18:15-22:00 UTC+8
22 June 2020
16:00-17:00 UTC+8
23 June 2020
16:00-17:00 UTC+8
24 June 2020
16:00-17:00 UTC+8
Conference Title
2019 Deals Review & Deals in China
 
Pharmaceutical Packaging and Drug Delivery Device Updates
 
Best Practices in Pharmaceutical Remote Audits During COVID-19 and Beyond
How Indian API Register in China
 
Continuous Manufacturing of Drug Products Opportunities and Challenges
The CPhI & P-MEC China team look forward to meeting you online!

No comments:

Post a Comment